Trials / Withdrawn
WithdrawnNCT01663415
A Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 2, Multicenter, Single-arm Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Astellas Pharma Global Development, Inc. · Industry
- Sex
- Male
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate radiographic progression-free survival (PFS) of enzalutamide in chemotherapy-naïve patients with progressive metastatic castration-resistant prostate cancer who have symptomatic disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Enzalutamide | oral |
Timeline
- Start date
- 2012-08-01
- Primary completion
- 2014-10-01
- Completion
- 2014-10-01
- First posted
- 2012-08-13
- Last updated
- 2012-09-17
Source: ClinicalTrials.gov record NCT01663415. Inclusion in this directory is not an endorsement.